FDA.reportPublic FDA data

SENSORCAINE

Product NDC
63323-472
11-digit product format
633230472
Labeler code
63323
Product ID
63323-472_cc1f6507-eb3e-4398-a1d3-0c56a2099e6b
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
BUPIVACAINE HYDROCHLORIDE
Dosage form
INJECTION, SOLUTION
Route
EPIDURAL; RETROBULBAR
Labeler
Fresenius Kabi USA, LLC
Application
ANDA070554
Marketing category
ANDA
Marketing start
2010-11-19
Substance
BUPIVACAINE HYDROCHLORIDE
Active strength
7.5 mg/mL
Pharmacologic classes
Amide Local Anesthetic [EPC], Amides [CS], Local Anesthesia [PE]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct63323-472DDiscontinued by firm2026-07-31
excluded productproduct63323-472DDiscontinued by firm2026-07-31
excluded packagepackage63323-47263323-472-33DDiscontinued by firm2026-07-31
excluded packagepackage63323-47263323-472-17DDiscontinued by firm2026-07-31
excluded packagepackage63323-47263323-472-37DDiscontinued by firm2026-07-31

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A070554-001SENSORCAINEBUPIVACAINE HYDROCHLORIDE0.75%INJECTABLE / INJECTIONAP1986-05-21

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A070554-001AP

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
SENSORCAINEBUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATEFresenius Kabi USA, LLCbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb2023-04-30Boxed warning, Warnings, Adverse reactionsExact identifier

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

boxed warning

WARNING: RISK OF CARDIAC ARREST WITH USE OF SENSORCAINE IN OBSTETRICAL ANESTHESIA There have been reports of cardiac arrest with difficult resuscitation or death during use of SENSORCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of SENSORCAINE is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary [see Warnings and Precautions ( 5.1 )]. WARNING: RISK OF CARDIAC ARREST WITH USE OF SENSORCAINE IN OBSTETRICAL ANESTHESIA See full prescribing information for complete boxed warning. There have been reports of cardiac arrest with difficult resuscitation or death during use of SENSORCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of SENSORCAINE is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary ( 5.1 ).

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Dose-Related Toxicity : Monitor cardiovascular and respiratory vital signs and patient's state of consciousness after injection of SENSORCAINE/ SENSORCAINE WITH EPINEPHRINE. ( 5.2 ) Methemoglobinemia : Cases of methemoglobinemia have been reported in association with local anesthetic use. See full prescribing information for more detail on managing these risks. ( 5.3 ) Chondrolysis with Intra-Articular Infusion : Intra-articular infusions of local anesthetics including SENSORCAINE following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. ( 5.5 ) Risk of Cardiac Arrest with Intravenous Regional Anesthesia Use (Bier Block) : There have been reports of cardiac arrest and death during the use of bupivacaine for intravenous regional anesthesia (Bier Block). ( 5.7 ) Allergic-Type Reactions to Sulfites in SENSORCAINE WITH EPINEPHRINE : SENSORCAINE WITH EPINEPHRINE contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. ( 5.8 ) Risk of Systemic Toxicities with Unintended Intravascular or Intrathecal Injection : Unintended intravascular or intrathecal injection may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspirate for blood or cerebrospinal fluid (where applicable) prior to each dose and consider using a test dose of SENSORCAINE-MPF WITH EPINEPHRINE. ( 5.9 ) 5.1 Risk of Cardiac Arrest with Use of SENSORCAINE in Obstetrical Anesthesia There have been reports of cardiac arrest with difficult resuscitation or death during use of SENSORCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of SENSORCAINE is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relax...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions section of the labeling: Cardiac Arrest in Obstetrical Anesthesia [see Warnings and Precautions ( 5.1 )] Dose-Related Toxicity [see Warnings and Precautions ( 5.2 )] Methemoglobinemia [see Warnings and Precautions ( 5.3 )] Chondrolysis with Intra-Articular Infusion [see Warnings and Precautions ( 5.5 )] Severe, Persistent Hypertension, Cerebrovascular Accidents, and Bradycardia Due to Drug Interactions [see Warnings and Precautions ( 5.6 )] Cardiac Arrest with Intravenous Regional Anesthesia Use [see Contraindications ( 4 ), Warnings and Precautions ( 5.7 )] Allergic-Type Reactions [see Warnings and Precautions ( 5.8 )] Systemic Toxicities with Unintended Intravascular or Intrathecal Injection [see Warnings and Precautions ( 5.9 )] Respiratory Arrest Following Retrobulbar Block [see Warnings and Precautions ( 5.15 )] The following adverse reactions from voluntary reports or clinical studies have been reported with bupivacaine or bupivacaine and epinephrine. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions to SENSORCAINE/ SENSORCAINE WITH EPINEPHRINE are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation. The most commonly encountered acute adverse reactions that demand immediate counter-measures were related to the CNS and the cardiovascular system. These adverse reactions were generally dose-related and due to high plasma levels which may have resulted from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional intrathecal injection of drug during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) has resulted in underventilation or apnea (“Total or High Spinal”). Also, hypotension d...

Additional Listing Data#

Finished product
Yes
Brand name base
SENSORCAINE
Brand name suffix
MPF
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
BUPIVACAINE HYDROCHLORIDE7.5 mg/mL

Harmonized Identifiers#

Field, Values table
FieldValues
Unii30Q7KI53AK, 7TQO7W3VT8
Rxcui1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810, 1867594, 1867596, 1867618, 1867620

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0b4ec9ca-d305-43fc-88dd-7a510313efe0Product name120260105
bb209f42-a85f-4fee-9d3d-c9dded168625Product name120251208
49628fc7-2031-4c28-bd31-0ef3aa8f44a3Product name320251118
cbf85893-59ef-423f-87d4-a573c000a8b9Product name820250731
b5b1095b-40cd-8a9e-b111-502545045b07Product name420250325
e190029e-423b-473c-8e04-2ada59b5b711Product name120250314
5dad6767-dcd1-b0da-8727-7f3f7bc3a435Product name220250303
e0031c74-3853-42bc-8e10-86dbbe83992eProduct name220231116
f7046b89-2016-499a-adc6-78479172abc6Product name120230425
e3a99641-4540-4894-9108-00cab3c57b7eProduct name120211207
5da98533-f072-406b-9e1b-6ac19eca9926Product name120210622
306b993e-3140-4823-ad5e-88b708f9d2acProduct name120210510
a831e694-3663-4a83-82be-6c309429f750Product name220200608
2686d634-e712-4007-8dbf-3d37c6c4d71fProduct name120181121
fa8b5901-e681-426f-82fe-54f6d81ec698Product name420180619
bd49bb86-2d32-4a7a-a594-eeda2e29af42Product name120180118
c08ab52f-2fc8-4409-9d9f-ed8edc0bd070Product name120171221
3becbe78-12d9-4ad2-9b4c-1e36f8d1303aProduct name120170815

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
63323-472-01SENSORCAINEMPF30 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION307
63323-472-03SENSORCAINEMPF10 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION107
63323-472-17SENSORCAINEMPF25 in 1 TRAYINJECTION, SOLUTION257
63323-472-37SENSORCAINEMPF25 in 1 TRAYINJECTION, SOLUTION257

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
63323-472-01ML - Milliliter63323-472c80ec71b-5e22-4442-bfa7-680a2d9a272912022-12-07
63323-472-03ML - Milliliter63323-472d55b90ab-f67f-4735-a7bd-1e58502f196012022-04-06
63323-472-17ML - Milliliter63323-472eb8b4441-a708-44a0-895b-fc23777d15b812012-07-24
63323-472-33ML - Milliliter63323-47256027130-de10-4c49-bef2-bf2b3f4ba0d112012-07-24
63323-472-37ML - Milliliter63323-4725c74ff5f-2fe8-4015-ab09-1bf688f1f68012012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
BUPIVACAINE HYDROCHLORIDEACTIVE INGREDIENT7TQO7W3VT8SENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
EPINEPHRINE BITARTRATEACTIVE INGREDIENT30Q7KI53AKSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
BUPIVACAINEACTIVE MOIETYY8335394ROSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
EPINEPHRINEACTIVE MOIETYYKH834O4BHSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QPSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CBSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9TSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8XSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32ISENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4
SODIUM METABISULFITEINACTIVE INGREDIENT4VON5FNS3CSENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]4

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
63323-472SENSORCAINE MPF (BUPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION SENSORCAINE (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ]7Current NDC, Legacy NDC, 4 package rows20230712_bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1867594BUPivacaine HCl 0.25 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867596BUPivacaine HCl 0.25 % / EPINEPHrine 1:200,000 in 30 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012377BUPivacaine HCl 0.25 % / EPINEPHrine 1:200,000 Injectable SolutionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012384BUPivacaine HCl 0.5 % / EPINEPHrine 1:200,000 Injectable SolutionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724787BUPivacaine HCl 0.75 % in 10 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724786BUPivacaine HCl 0.75 % in 30 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867618Sensorcaine 0.25 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867620Sensorcaine 0.25 % / EPINEPHrine 1:200,000 in 30 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012413Sensorcaine 0.25 % / EPINEPHrine 1:200,000 Injectable SolutionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012417Sensorcaine 0.5 % / EPINEPHrine 1:200,000 Injectable SolutionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724809Sensorcaine 0.75 % in 10 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724810Sensorcaine 0.75 % in 30 ML InjectionPSNbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
186761810 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection [Sensorcaine with Epinephrine]SBDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
172480910 ML bupivacaine hydrochloride 7.5 MG/ML Injection [Sensorcaine]SBDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
186762030 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injection [Sensorcaine with Epinephrine]SBDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
172481030 ML bupivacaine hydrochloride 7.5 MG/ML Injection [Sensorcaine]SBDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012413bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injectable Solution [Sensorcaine with Epinephrine]SBDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012417bupivacaine hydrochloride 5 MG/ML / epinephrine 0.005 MG/ML Injectable Solution [Sensorcaine with Epinephrine]SBDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
186759410 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML InjectionSCDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
172478710 ML bupivacaine hydrochloride 7.5 MG/ML InjectionSCDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
186759630 ML bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML InjectionSCDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
172478630 ML bupivacaine hydrochloride 7.5 MG/ML InjectionSCDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012377bupivacaine hydrochloride 2.5 MG/ML / epinephrine 0.005 MG/ML Injectable SolutionSCDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012384bupivacaine hydrochloride 5 MG/ML / epinephrine 0.005 MG/ML Injectable SolutionSCDbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
172480910 ML Sensorcaine 7.5 MG/ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
172481030 ML Sensorcaine 7.5 MG/ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867594bupivacaine HCl 0.25 % / epinephrine (as bitartrate) 1:200,000 per 10 mL InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867596bupivacaine HCl 0.25 % / epinephrine 1:200,000 per 30 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724787bupivacaine HCl 0.75 % in 10 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724786bupivacaine HCl 0.75 % in 30 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724786bupivacaine HCl 225 MG per 30 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724787bupivacaine HCl 75 MG per 10 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012377bupivacaine hydrochloride 0.25 % / epinephrine (as epinephrine bitartrate) 1:200,000 Injectable SolutionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012384bupivacaine hydrochloride 0.5 % / epinephrine (as epinephrine bitartrate) 1:200,000 Injectable SolutionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012413Sensorcaine 0.25 % / EPINEPHrine 1:200,000 Injectable SolutionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867618Sensorcaine 0.25 % / EPINEPHrine 1:200,000 per 10 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1867620Sensorcaine 0.25 % / EPINEPHrine 1:200,000 per 30 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012413Sensorcaine with Epinephrine 0.25/1:200000 (bupivacaine hydrochloride / epinephrine (as epinephrine bitartrate) ) Injectable SolutionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012417Sensorcaine with Epinephrine 0.5/1:200000 (bupivacaine hydrochloride / epinephrine (as epinephrine bitartrate) ) Injectable SolutionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1012417Sensorcaine-MPF 0.5 % / epinephrine 1:200,000 Injectable SolutionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724809Sensorcaine-MPF 0.75 % in 10 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7
1724810Sensorcaine-MPF 0.75 % in 30 ML InjectionSYbc61a9a6-0a4e-48a9-b908-e5e66b9f23eb7

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
63323-472-016332304720130 mL in 1 VIAL, SINGLE-DOSE30 mlHistorical
63323-472-036332304720310 mL in 1 VIAL, SINGLE-DOSE10 mlHistorical
63323-472-176332304721725 VIAL, SINGLE-DOSE in 1 TRAY (63323-472-17) / 10 mL in 1 VIAL, SINGLE-DOSE (63323-472-03) 2010-11-190000-00-00NoNoCurrent
63323-472-376332304723725 VIAL, SINGLE-DOSE in 1 TRAY (63323-472-37) / 30 mL in 1 VIAL, SINGLE-DOSE (63323-472-01) 2010-11-190000-00-00NoNoCurrent